Cipher Pharmaceuticals Stock Shares Owned By Insiders
| CPHRFDelisted Stock | USD 2.57 0.00 0.00% |
Cipher Pharmaceuticals fundamentals help investors to digest information that contributes to Cipher Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Cipher OTC Stock. The fundamental analysis module provides a way to measure Cipher Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cipher Pharmaceuticals otc stock.
Cipher |
Cipher Pharmaceuticals OTC Stock Shares Owned By Insiders Analysis
Cipher Pharmaceuticals' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Cipher Pharmaceuticals Shares Owned By Insiders | 44.12 % |
Most of Cipher Pharmaceuticals' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cipher Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
CompetitionBased on the latest financial disclosure, 44.12% of Cipher Pharmaceuticals are shares owned by insiders. This is 190.65% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The shares owned by insiders for all United States stocks is notably lower than that of the firm.
Cipher Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cipher Pharmaceuticals' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Cipher Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Cipher Pharmaceuticals by comparing valuation metrics of similar companies.Cipher Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers.
Cipher Fundamentals
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.45 % | ||||
| Operating Margin | 0.57 % | ||||
| Current Valuation | 46.13 M | ||||
| Shares Outstanding | 25.12 M | ||||
| Shares Owned By Insiders | 44.12 % | ||||
| Number Of Shares Shorted | 11.43 K | ||||
| Price To Earning | 15.54 X | ||||
| Price To Book | 1.63 X | ||||
| Price To Sales | 3.28 X | ||||
| Revenue | 21.94 M | ||||
| Gross Profit | 18.26 M | ||||
| EBITDA | 11.85 M | ||||
| Net Income | 7.76 M | ||||
| Cash And Equivalents | 24.19 M | ||||
| Cash Per Share | 0.96 X | ||||
| Total Debt | 507 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 2.51 X | ||||
| Book Value Per Share | 1.77 X | ||||
| Cash Flow From Operations | 13.81 M | ||||
| Short Ratio | 0.97 X | ||||
| Earnings Per Share | 0.36 X | ||||
| Target Price | 5.59 | ||||
| Number Of Employees | 26 | ||||
| Beta | 1.03 | ||||
| Market Capitalization | 64.32 M | ||||
| Total Asset | 51.65 M | ||||
| Z Score | 75.6 | ||||
| Net Asset | 51.65 M |
About Cipher Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cipher Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cipher Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cipher Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Cipher OTC Stock
If you are still planning to invest in Cipher Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cipher Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |